In a study involving 806 cognitively normal (CN) participants, 35 MCI patients, and 35 AD patients, ApoE ε4 carriers exhibited significantly lower glucose metabolism in multiple brain regions, including those characteristic of AD, compared to non-carriers. The gene discussed is APOE; the disease is Alzheimer disease.